Skip to main content
. 2020 Jan 23;9:1534. doi: 10.3389/fonc.2019.01534

Figure 11.

Figure 11

Anti-tumor efficacy of ST8176AA1 in PDX pancreatic carcinoma model of PA5366. (A) NODSCID mice (10/group) bearing patient-derived pancreatic carcinomas PA5366 were treated i.p. with ST8176AA1 or trastuzumab (5 doses of 15 mg/kg once every 4 days, starting 36 days after tumor transplantation as indicated by arrows in the graph). One group received vehicle (PBS) with the same schedule. Tumor growth was monitored using a Vernier caliper. Data are expressed as mean ± SE. Statistical analysis by Mann-Whitney's test. *P < 0.05 vs. vehicle and °P < 0.05 vs. trastuzumab. (B) Tumor masses at the end of the study were analyzed by immunohistochemistry. Cells positive for acetyl-histone H3 from PA5366 were counted by two independent observers in five randomly selected fields. Data in the graph are expressed as the mean of positive cells × 100/total cells ± SE or as score with negative staining, score 0; 1-20% positive cells, score 1+; 21-50% positive cells, score 2+ >50% positive cells, score 3+. Statistical analysis by Mann-Whitney's test. *P < 0.05 vs. vehicle-treated group; °°P < 0.01 vs. trastuzumab. (C) Representative immunohistochemistry pictures for acetyl-histone H3 are shown. Images captured using 40 × magnification. Scale bar: 500 μm.